Cellectis S.A. stock is up 3.53% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January.
Cellectis S.A. develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!